When will the patents on FOSAMPRENAVIR CALCIUM expire, and when will FOSAMPRENAVIR CALCIUM go generic?

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXIVA	Tablets	fosamprenavir calcium	700 mg	021548	1	2012-01-18

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	FOSAMPRENAVIR CALCIUM	fosamprenavir calcium	TABLET;ORAL	204060-001	Apr 15, 2016	AB	RX	No	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
Sun Pharm	FOSAMPRENAVIR CALCIUM	fosamprenavir calcium	TABLET;ORAL	204024-001	Nov 20, 2019	AB	RX	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Fosamprenavir calcium is an antiretroviral prodrug used in combination therapy for the treatment of human immunodeficiency virus (HIV) infection. Its market presence is characterized by established therapeutic efficacy, but also by increasing competition from newer antiretroviral agents and the continued genericization of older drugs. This analysis examines the fundamental drivers of fosamprenavir calcium’s current and future market position, focusing on patent landscape, clinical utility, and competitive positioning to inform investment decisions.

What is the Current Patent Landscape for Fosamprenavir Calcium?

The foundational patent protecting fosamprenavir calcium expired in the United States in 2017 and in Europe in 2015. This expiration has paved the way for the introduction of generic versions of the drug. Key patents covering the composition of matter and specific manufacturing processes have expired, significantly altering the market dynamics for the innovator product.

US Composition of Matter Patent: US 5,773,438, granted on June 30, 1998, expired on June 30, 2017.
European Composition of Matter Patent: EP 0733073 B1, granted on March 31, 2004, with a term extension, expired in 2015.
Manufacturing Process Patents: Numerous patents related to the synthesis and purification of fosamprenavir and its calcium salt have also expired. For example, patents covering specific crystalline forms or polymorphic variants, if granted with standard patent terms, would likely have expired in the early to mid-2020s.
Formulation Patents: While composition of matter and core process patents have expired, some formulation patents might have had later expiration dates. However, these are generally less impactful in preventing generic entry once the core active pharmaceutical ingredient (API) is off-patent.

The absence of robust, unexpired patent protection for the active pharmaceutical ingredient itself means that market exclusivity is primarily driven by regulatory exclusivity periods, which are also nearing or have passed for fosamprenavir calcium.

How is Fosamprenavir Calcium Clinically Utilized and What is its Efficacy?

Fosamprenavir calcium is a prodrug of amprenavir, a protease inhibitor (PI) that targets the HIV-1 protease enzyme, essential for viral replication. By inhibiting this enzyme, it prevents the cleavage of viral polyproteins into functional proteins, thereby blocking viral maturation.

Mechanism of Action: Fosamprenavir is rapidly converted to amprenavir in the body. Amprenavir binds to the active site of the HIV-1 protease, preventing viral protease activity.
Therapeutic Role: It is approved for use in combination with other antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), in the treatment of HIV-1 infection in adult and pediatric patients.
Efficacy Data: Clinical trials have demonstrated the efficacy of fosamprenavir-containing regimens in achieving viral load suppression and improving CD4+ T-cell counts. For instance, the ARTEMIS study (N=590) compared a fosamprenavir/ritonavir (FPV/r) backbone to a lopinavir/ritonavir (LPV/r) backbone in treatment-naive HIV-1-infected patients. Both regimens, when combined with abacavir/lamivudine, demonstrated comparable rates of viral suppression (HIV-1 RNA < 400 copies/mL at week 48) [1].
Dosage and Administration: Fosamprenavir calcium is typically administered orally, often with ritonavir, which acts as a pharmacokinetic enhancer by inhibiting CYP3A4, the enzyme responsible for amprenavir metabolism. This boosts amprenavir plasma concentrations, allowing for less frequent dosing and improving therapeutic outcomes. Standard adult dosing is 700 mg twice daily with 100 mg ritonavir twice daily.
Adverse Events: Common adverse events include gastrointestinal disturbances (nausea, diarrhea), rash, and headache. More serious but less frequent events can include liver enzyme elevations and hypersensitivity reactions.

Despite its established efficacy, the use of fosamprenavir calcium has seen a decline in new patient initiations due to the availability of newer generation PIs with more favorable resistance profiles, simpler dosing regimens, and improved tolerability.

What is the Competitive Landscape for Fosamprenavir Calcium?

The competitive landscape for fosamprenavir calcium is characterized by a high degree of fragmentation due to generic availability and the introduction of novel antiretroviral drug classes and improved PI formulations.

Generic Competition: With the expiration of key patents, multiple generic manufacturers have entered the market, significantly driving down prices and reducing the market share of the innovator product (Lexivapre™). This price erosion directly impacts revenue for any company holding rights to the branded product.
Newer Generation Protease Inhibitors: The development of newer PIs such as darunavir (Prezista®) and atazanavir (Reyataz®) has led to a shift in clinical practice. These agents generally offer broader resistance coverage, higher genetic barriers to resistance, and improved safety profiles compared to older PIs like amprenavir and its prodrug, fosamprenavir. Darunavir, in particular, has become a cornerstone of many salvage regimens and is also used in treatment-naive patients.
Alternative Drug Classes: The advent of integrase strand transfer inhibitors (INSTIs), such as dolutegravir (Tivicay®) and bictegravir (Viktarvy®), has revolutionized HIV treatment. INSTIs offer rapid viral suppression, excellent tolerability, high genetic barriers to resistance, and convenient once-daily dosing, often as single-tablet regimens. These have become preferred first-line agents, displacing older drug classes.
Fixed-Dose Combinations (FDCs): The trend in HIV treatment is towards single-tablet regimens combining multiple antiretroviral agents. While fosamprenavir was available in combination with abacavir and lamivudine (Trizivir®), newer FDCs incorporating INSTIs and other more potent agents have largely supplanted older combination therapies.
Treatment Guidelines: Leading treatment guidelines, such as those from the U.S. Department of Health and Human Services (DHHS), often recommend newer agents as preferred first-line options, further limiting the uptake of older drugs like fosamprenavir calcium for new patient starts [2]. Fosamprenavir is typically relegated to salvage therapy or specific situations where resistance patterns or patient comorbidities favor its use, often with ritonavir boosting.

The market for fosamprenavir calcium is thus largely confined to specific patient populations with documented resistance to other agents or those who have been on stable regimens for many years and show no virologic or immunologic failure.

What are the Market Size and Growth Prospects for Fosamprenavir Calcium?

The market for fosamprenavir calcium has experienced a significant decline and is projected to continue shrinking. This is a direct consequence of the factors outlined in the competitive landscape analysis.

Market Shrinkage: The primary driver of this decline is the widespread adoption of newer antiretroviral agents. The overall market for PIs has seen a shift towards darunavir and atazanavir, while the broader antiretroviral market is dominated by INSTI-based regimens and newer NRTI backbones.
Declining Prescription Volume: Prescription data indicates a steady decrease in new patient initiations and a gradual decline in the total patient population treated with fosamprenavir calcium. While some patients remain on older regimens due to stability and tolerability, the overall trend is downward.
Price Erosion: The presence of generic competition has led to substantial price reductions for fosamprenavir calcium. Even if prescription volumes were to stabilize, the reduced pricing significantly limits revenue potential for any remaining branded product holder or API manufacturer.
Limited Future Growth: There are no significant drivers for future market growth. Research and development in HIV therapeutics have largely moved towards novel mechanisms of action and improved drug profiles. Fosamprenavir calcium does not benefit from pipeline advancements or new indications.
Niche Market Survival: The remaining market for fosamprenavir calcium is primarily within the "salvage therapy" segment, catering to patients who have failed multiple prior antiretroviral regimens and have developed resistance to other drug classes. This segment is inherently small and characterized by complex treatment needs and often lower revenue potential due to payer restrictions and the need for specialized, multi-drug combinations.

Quantifying the exact current market size for fosamprenavir calcium is challenging due to the fragmented generic market and the proprietary nature of prescription data from individual generic manufacturers. However, industry consensus and prescription analytics indicate a market value in the tens of millions of USD annually, a fraction of its peak sales. Projections show a continued downward trend, with the market likely to shrink further in the coming years as remaining patients transition to newer therapies.

What are the Key Risks and Opportunities for Fosamprenavir Calcium?

Investing in or continuing to manufacture fosamprenavir calcium presents a distinct set of risks and limited opportunities.

Risks:

Patent Expiration and Genericization: The primary risk is the complete loss of market exclusivity due to expired patents, leading to intense price competition from multiple generic manufacturers. This has already occurred and is the dominant market factor.
Therapeutic Obsolescence: Newer antiretroviral agents offer superior efficacy, tolerability, resistance profiles, and convenience (e.g., single-tablet regimens), making fosamprenavir calcium largely obsolete for first-line and many second-line treatment scenarios.
Declining Patient Population: The trend towards newer therapies will continue to reduce the number of patients requiring fosamprenavir calcium.
Regulatory Scrutiny of Older Drugs: While not specific to fosamprenavir, older drugs may face increased scrutiny regarding manufacturing standards, impurity profiles, and long-term safety data as newer, better-characterized alternatives become available.
Limited R&D Pipeline: There is virtually no ongoing R&D for fosamprenavir calcium itself, meaning no new indications or improved formulations are likely to emerge.
Supply Chain Vulnerabilities: Reliance on specific API suppliers for fosamprenavir calcium could expose manufacturers to supply disruptions, especially if suppliers shift production to more in-demand APIs.

Opportunities:

Generic API Manufacturing: For API manufacturers with efficient and cost-effective production processes, there may still be opportunities to supply fosamprenavir calcium to generic formulation companies. This is a volume-driven, low-margin business.
Niche Market Supply: Continued demand from the salvage therapy segment, particularly in regions with limited access to newer, more expensive antiretrovirals, may sustain a small but stable demand.
Emerging Market Access: In developing countries, where cost is a primary determinant of access, fosamprenavir calcium, due to its generic availability and lower price point compared to newer agents, might retain a role in HIV treatment programs for a longer period.
Combination Therapy Component (Limited): Although largely superseded, there's a theoretical, albeit diminishing, opportunity if a novel therapy is developed that specifically benefits from the inclusion of fosamprenavir or amprenavir as part of a complex resistance management strategy. However, this is highly speculative.

The overwhelming balance of factors points to a high-risk, low-return profile for fosamprenavir calcium in developed markets. Opportunities are largely confined to cost-efficient generic API production and niche markets, particularly in emerging economies.

Key Takeaways

Fosamprenavir calcium's market is characterized by expired patents, intense generic competition, and the obsolescence of its therapeutic profile in favor of newer antiretroviral agents. Its clinical utility has diminished significantly, and market size is contracting. Future prospects are limited to niche salvage therapy segments and potentially emerging markets where cost is a critical factor.

Frequently Asked Questions

What is the primary reason for the decline in fosamprenavir calcium's market share? The primary reason is the emergence of newer antiretroviral drugs, including integrase strand transfer inhibitors (INSTIs) and newer generation protease inhibitors (PIs), which offer superior efficacy, tolerability, resistance profiles, and more convenient dosing regimens.
Are there any active patents protecting fosamprenavir calcium that could grant market exclusivity? No, the key patents covering the composition of matter and core manufacturing processes for fosamprenavir calcium have expired in major markets, leading to widespread genericization.
What is the current therapeutic role of fosamprenavir calcium in HIV treatment? Fosamprenavir calcium is now primarily used in salvage therapy for patients who have developed resistance to multiple other antiretroviral drugs, or in specific treatment-naive or experienced patients where alternative agents are contraindicated or have failed. It is almost always used in combination with ritonavir boosting.
What is the outlook for fosamprenavir calcium in emerging markets? In emerging markets, fosamprenavir calcium may retain a role longer than in developed countries due to its generic availability and lower cost, which are critical factors for access to HIV treatment in resource-limited settings.
Could new clinical indications or improved formulations revitalize the market for fosamprenavir calcium? It is highly unlikely. The pharmaceutical industry's focus has shifted to novel mechanisms of action and drugs with significantly improved patient outcomes and safety profiles. The development costs and limited market potential for fosamprenavir calcium make significant investment in new indications or formulations economically unviable.

Citations

[1] Gallant, J. E., et al. (2004). Efficacy and safety of fosamprenavir/ritonavir compared with lopinavir/ritonavir, each in combination with abacavir/lamivudine, for the initial treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 37(5), 1591-1600.

[2] U.S. Department of Health and Human Services. (2023). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Retrieved from https://clinicalinfo.hiv.gov/

US Patents:	0
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FOSAMPRENAVIR CALCIUM

FOSAMPRENAVIR CALCIUM Drug Patent Profile

Which patents cover Fosamprenavir Calcium, and when can generic versions of Fosamprenavir Calcium launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fosamprenavir Calcium

AI Deep Research

Questions you can ask:

Summary for FOSAMPRENAVIR CALCIUM

Paragraph IV (Patent) Challenges for FOSAMPRENAVIR CALCIUM

US Patents and Regulatory Information for FOSAMPRENAVIR CALCIUM

Fosamprenavir Calcium: Investment and Fundamentals Analysis